Navigation Links
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:2/25/2008

Negative Symptom Scale) Excited Component (also known as PEC) score, measured at 2 hours after the first dose. Various assessments of a patient's agitation state will be conducted at serial time points using standard agitation scales over the first 4-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects will be recorded throughout the 24-hour period.

A second Phase 3 clinical trial is projected to begin in Q3 2008. The design of the second study will be similar to the first trial, except that the patient population will be patients with bipolar disease.

About Acute Agitation

Acute agitation, characterized by unpleasant arousal, tension, irritability and hostility, is one of the most common and severe symptoms of many major psychiatric disorders, including schizophrenia and bipolar disorder. According to the National Institute of Mental Health (NIMH), schizophrenia afflicts about 2.4 million people in the United States and bipolar disease affects about 5.7 million American adults. We believe over 90% of these patients will experience agitation during their lifetime and that about 70% of those who experience agitation will have one to six episodes per year.

Agitated patients are often treated in an emergency room setting, and are also treated as in-patients in psychiatric hospitals or psychiatric units in standard hospitals. We believe physicians currently treat acute agitation with intramuscular (IM) injections, rapid-dissolve tablets or standard tablets. IM injections are invasive, can be disconcerting to patients as they often require the use of restraints, and can be dangerous to the medical personnel while they attempt to inject the patient. IM injections can also take up to 60 minutes to work. Oral tablets provide convenience of dosing alternatives and have a slower onset of action. Market research among physicians has identified speed of onset as an important factor that affects
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Silicon Valley Electronic ... with RPM Alliance , provider of clinical research ... With the latest addition to its CRO Partnership Program, ... EDC system to India. , “We have found ... and customizable EDC platform which is both user friendly ...
(Date:11/26/2014)... November 25, 2014 The Pittcon marketing ... official conference and exposition mobile app, ... download in the App Store for iOS and Android ... resource tool before, during and after the event. It ... on exhibiting companies, technical sessions, Conferee Networking sessions and ...
(Date:11/26/2014)... 2014 Miles Holder, formerly of Micron ... Carbon Products team as Sales/Marketing Manager. Mr. Holder has ... service for the graphite industry. , “We are thrilled ... stated Dave Trinkley, VP of Market and Product Development ... experience in the graphite industry, along with his proven ...
(Date:11/26/2014)... and WILMINGTON, DE (PRWEB) November 26, 2014 ... Annual MPN Heroes recognition reception on December 5, 2014, ... Hematology’s annual meeting. The MPN Heroes event will honor ... in the field of myeloproliferative neoplasms (MPNs). , ... "Nashville," will discuss his family's cancer journey at the ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2Pittcon Releases 2015 Mobile App 2Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4
... Stock Symbol ,OGXI, Implements immediate restructuring ... focusing on clinical pipeline programs BOTHELL, ... (formerly Sonus Pharmaceuticals, Inc.) (NASDAQ: OGXI ... completed its acquisition of,OncoGenex Technologies and NASDAQ ...
... China, Aug. 21 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. ... a leading Chinese firm specializing in ... of probiotics products,today announced it signed ... Co., Ltd. ("Square Pharmaceutical") to supply ...
... Clinical Environments - Without the High Costs of Regular ... ... OAKLAND, Calif., Aug. 21 LUMEDX Corporation, a leading,provider ... Products, introduce CardioECG 3.2,multi-modality, multi-vendor, pure-Web software for cardiac rhythm ...
Cached Biology Technology:Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 2China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base 3LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution 2
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/3/2014)... Cancer Center study published in this month,s ... describes the activity of a recently discovered communication molecule ... It has been known to limit inflammation and the ... system: IL-37 inhibits the ability of the immune system ... mechanism that underlies IL-37,s effect on the immune system ...
(Date:11/2/2014)... support of a bold quest to rid the world ... today announced an award of US$156 million to PATH ... building new vaccines that will interrupt the cycle of ... zero" agenda. Such vaccines would ensure that parasite reintroduction ... "immunological bed net." , This approach to developing ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... MIAMI November 5, 2012 -- A new study by ... Marine & Atmospheric Science uses Interferometric Synthetic Aperture Radar (InSAR) ... volcanoes in Indonesia,s west Sunda arc. Led by geophysicist Estelle ... that several volcanoes did in fact ,inflate, prior to eruptions ...
... NC Researchers have discovered why plants and animals had ... Earth,s history 250 million years ago. The reason: global ... species that survived the extinction didn,t fully recover for 5 ... the story of how life was forever altered by giant ...
... of the 2013 Distinguished Service Award, the Emily M. Gray ... be honored at the National Lecture on Monday, February 4, ... also give a presentation at the Undergraduate Student Symposium on ... Klaus Schulten, University of Illinois, Urbana Champaign, will receive ...
Cached Biology News:Taking the 'pulse' of volcanoes using satellite images 2After long-ago mass extinction, global warming hindered species' recovery 2After long-ago mass extinction, global warming hindered species' recovery 3After long-ago mass extinction, global warming hindered species' recovery 4
... MW 140kDa GenBank ... Peptide spanning amino acids 926-941 (DKKVKPPFIPTIRGRE) of ... purified Quality Assurance Routinely ... HeLa cells. Stability 1 ...
Immunogen: MBP-fusion protein of the C-terminal region of the a2 subunit (amino acids K581-D670) Storage: -20 C, Avoid Freeze/Thaw Cycles...
MarrowMAX Bone Marrow Medium...
Replacement Parts for Electrophoresis Apparatus...
Biology Products: